A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

NCT06759636 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

88

Enrollment

OTHER

Sponsor class

Conditions

CTIT: Cancer Therapy Induced Thrombocytopenia

Interventions

DRUG: Romiplostim N01
DRUG: Recombinant Human Interleukin-11 (rhIL-11)

Sponsor

The First Affiliated Hospital with Nanjing Medical University